Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31022689 | 0.84 | TSHR (0.38) | TSHRMAPK1CYP1A2MEN1KMT2A | |
| SCHEMBL15910175 | 0.83 | GABRR1 (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL8148471 | 0.82 | GABRR1 (0.38) | GABRR1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL13498545 | 0.82 | TSHR (0.39) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL3283814 | 0.82 | HSD17B10 (0.54) | GABRR1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL15701348 | 0.81 | — | — | |
| SCHEMBL3632408 | 0.80 | GABRR1 (0.37) | ALDH1A1GABRR1CYP1A2NOS3NOS1 | |
| SCHEMBL2908572 | 0.80 | GABRR1 (0.37) | GABRR1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL13434973 | 0.80 | BLM (0.45) | MAPK1ALDH1A1GABRR1CYP1A2NOS3 | |
| SCHEMBL14177527 | 0.80 | GABRR1 (0.37) | ALDH1A1GABRR1CYP1A2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-8361961-B2 | O-linked glycosylation of peptides | BIOGENERIX AG (DE) | 2013-01-29 | — | — | US | disclosed |
| US-8268967-B2 | Glycopegylated interferon α | NOVO NORDISK A/S (DK) | 2012-09-18 | — | — | US | disclosed |
| US-7842661-B2 | Glycopegylated erythropoietin formulations | NOVO NORDISK A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| US-20100210507-A9 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2010-08-19 | — | — | US | disclosed |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-04-01 | — | — | US | disclosed |
| US-20100009902-A1 | Glycoconjugation Using Saccharyl Fragments | NEOSE TECHNOLOGIES, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090169509-A1 | O-linked glycosylation of peptides | BIOGENERIX AG (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090028822-A1 | Glycopegylated Interferon Alpha | NEOSE TECHNOLOGIES, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | NOVO NORDISK A/S (DK) | 2008-01-17 | — | — | US | disclosed |
| US-20070254834-A1 | Glycopegylated Erythropoietin | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | NOVO NORDISK A/S (DK) | 2007-11-01 | — | — | US | disclosed |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NEOSE TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-6191321-B1 | PASSING METHYL 3-HYDROXYPROPIONATE TO A HYDROGENATION ZONE AND CONTACTING WITH HYDROGEN IN THE PRESENCE OF A COPPER ZINC OXIDE HYDROGENATION CATALYST TO PRODUCE HYDROGENATION MIXTURE CONTAINING 1,3-PROPANEDIOL AND RECOVERING THE 1,3-PROPANEDIOL | SHELL OIL COMPANY | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028822-A1 | Glycopegylated Interferon Alpha | IFNG, IFNAR1, OGT | TSHR 1369/4885MAPK1 4097/4885ALDH1A1 1918/4885 |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | TSHR 1149/4885MAPK1 1822/4885ALDH1A1 2807/4885 |
| US-20070254834-A1 | Glycopegylated Erythropoietin | EPOR, UGGT1, GNE | TSHR 755/4885MAPK1 3337/4885ALDH1A1 1029/4885 |
| US-20100210507-A9 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | TSHR 755/4885MAPK1 3337/4885ALDH1A1 1029/4885 |
| US-20100009902-A1 | Glycoconjugation Using Saccharyl Fragments | B3GAT3, UGGT1, UGCG | TSHR 2176/4885MAPK1 4362/4885ALDH1A1 1297/4885 |
| US-20070254836-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | CSF3R, GMFG, GALNT1 | TSHR 1795/4885MAPK1 3300/4885ALDH1A1 1451/4885 |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | TSHR 1474/4885MAPK1 3817/4885ALDH1A1 2154/4885 |
| US-20090169509-A1 | O-linked glycosylation of peptides | OGA, OGT, OSTC | TSHR 2659/4885MAPK1 3673/4885ALDH1A1 3143/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | TSHR 600/4885MAPK1 3270/4885ALDH1A1 2228/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | TSHR 1795/4885MAPK1 3300/4885ALDH1A1 1451/4885 |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | GHITM, PTMS, GHRHR | TSHR 323/4885MAPK1 4046/4885ALDH1A1 4799/4885 |
| US-20080015142-A1 | Glycopegylated Follicle Stimulating Hormone | FSHR, GNRHR, SHBG | TSHR 158/4885MAPK1 3351/4885ALDH1A1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.